Venezuela
Industry
BMI View: Corporate social responsibility (CSR) is an underappreciated business activity in the pharmaceutical industry. Like all commercial entities, drugmakers are fully entitled...
2012-01-13Industry
BMI View: Plans by the Venezuelan government to build pharmaceutical plants are unlikely to lower medicine costs for patients due to the inherent inefficiency of state-backed drugmakers...
2011-12-22Industry
BMI View: While Venezuela's increasingly harsh pricing regime looks unlikely to address persistent medicine shortages, President Hugo Chavez's renewed attempts to regulate the country's...
2011-12-07Industry
BMI View: While Venezuela's decision to formally regulate margins on goods and services, including healthcare, is likely to help President Hugo Chávez win political support and control...
2011-11-24Industry
BMI View: While we do not foresee an improvement in Cuba's overall business environment any time soon, we maintain that the country's biopharmaceutical sector remains largely under...
2011-11-07Industry
BMI View: Bucking a global push towards over-the-counter (OTC) medicines, governments across Latin America have responded to a series of scandals by clamping down on pharmacy sales....
2011-10-28Industry
BMI View: We see Teuto's decision to focus on advanced drug manufacturing systems, along with its product portfolio of innovative and generic medicines, as a further improvement in...
2011-09-23Industry
BMI View: Despite President Hugo Chavez's growing desire to strengthen Venezuela's healthcare infrastructure, we note price freezes have made the country's business environment increasingly...
2011-09-02




